Transgene’s combined general meeting 15
Category: Press release
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
Appointment of Carol Stuckley as New Independent Director 15
Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
Availability of Preparatory documents for the combined general meeting of May 5, 2023 15
Availability of Transgene’s 2022 Universal Registration Document
Availability of Transgene’s 2022 Universal Registration Document 15
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
Transgene to host KOL webinar on TG4050 15
Transgene Announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings 15
Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
2022 full-year results and business update 15
